Cayston
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead. It inhibits cell wall synthesis in aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, one of the most common pathogens found in patients with cystic fibrosis. Treatment with Cayston requires nebulization of the aztreonam solution, and the recommended dosing is three times daily.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Cayston : Cystic fibrosis
LIST OF FIGURES
12 Figure 1: Cayston for cystic fibrosis – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cayston for cystic fibrosis
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Cayston for cystic fibrosis
16 Figure 4: Cayston sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Cayston drug profile
8 Table 2: Cayston Phase III data in cystic fibrosis
17 Table 3: Cayston sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Bronchitol 
Sign up to the